Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00354068
Other study ID # Pro00004364
Secondary ID DUMC-5514-06-1R2
Status Completed
Phase Phase 1
First received July 19, 2006
Last updated March 26, 2013
Start date July 2004
Est. completion date November 2008

Study information

Verified date March 2013
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with temozolomide in treating patients with malignant glioma.


Description:

OBJECTIVES:

- Determine the maximum tolerated dose and dose-limiting toxicity, if attainable, of imatinib mesylate in combination with temozolomide in patients with malignant glioma.

- Characterize the safety and tolerability of imatinib mesylate, including acute and chronic toxicities, in these patients.

- Determine the effect of temozolomide on the pharmacokinetics (PK) of imatinib mesylate at each dose level.

- Evaluate the impact of enzyme-inducing anti-epileptic drug (EIAED) coadministration on the PK of imatinib mesylate using a population-based PK approach.

- Evaluate the antitumor activity of imatinib mesylate plus temozolomide.

OUTLINE: This is a dose-escalation study of imatinib mesylate. Patients are stratified according to concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine, fosphenytoin, primidone, oxcarbazepine) (yes vs no).

Patients receive oral imatinib mesylate once or twice daily on days 1-8 and oral temozolomide once daily on days 4-8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of patients receive escalating doses of imatinib mesylate until the maximum tolerated dose is determined.

On days 1 and 8 of course 1, blood is drawn for pharmacokinetic studies.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed malignant glioma

- Any of the following subtypes:

- Glioblastoma multiforme

- Gliosarcoma

- Anaplastic astrocytoma

- Anaplastic oligodendroglioma

- Anaplastic oligoastrocytoma

- Previous histologic diagnosis of a lower grade of glioma allowed if there is histologic evidence of progression to a diagnosis of malignant glioma

- Multifocal disease allowed

- Must have undergone prior conventional external-beam radiation therapy

- Stable disease, disease recurrence, or relapsed disease

- Must not have received any systemic therapy for this recurrence or relapse

- No prior progressive disease

- No central/systemic fluid collections (pericardial effusion, pulmonary effusion, ascites) = grade 2

- No evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative grade 1 hemorrhage

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Absolute neutrophil count > 1,500/mm³

- Hemoglobin > 9 g/dL

- Platelet count > 100,000/mm³

- AST and ALT < 2.5 times upper limit of normal (ULN)

- Bilirubin < 1.5 times ULN

- Creatinine < 1.5 times ULN

- No chronic renal disease

- No active uncontrolled infection

- No uncontrolled diabetes

- No excessive risk of bleeding, as defined by occurrence of any of the following:

- Stroke within the past 6 months

- History of CNS or intraocular bleed

- Septic endocarditis

- No history of labile hypertension

- No congestive heart failure

- No poorly controlled hypertension

- No myocardial infarction within the past 6 months

- No history of poor compliance with antihypertensive regimen

- No other severe and/or uncontrolled medical disease that would preclude study participation

- No peripheral edema = grade 2

- No gastrointestinal bleeding

- No gross hematuria

- No other active systemic bleeding

- Patients must not have experienced toxicity = grade 3 with prior treatment with either temozolomide or imatinib mesylate

- No other primary malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix or other cancer not currently clinically significant nor requiring active interventions

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from all prior therapy

- Prior surgical resection(s) allowed

- At least 2 weeks since prior surgery

- At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas)

- At least 2 weeks since prior external-beam radiotherapy

- At least 2 weeks since prior investigational drugs

- More than 1 week since prior biologic, immunotherapeutic, or cytostatic agents

- No concurrent warfarin

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
imatinib mesylate

temozolomide

Other:
pharmacological study


Locations

Country Name City State
United States Duke Cancer Institute Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus te — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose Yes
Primary Dose-limiting toxicity Yes
Primary Safety and tolerability Yes
Primary Pharmacokinetics No
Primary Anti-tumor activity No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1